SourceBio International plc
(“SourceBio”, the “Company” or the “Group”)
US expansion of COVID-19 testing services
COVID-19 testing services to be offered from San Diego facilities
SourceBio International plc (AIM: SBI), the international provider of integrated state-of-the-art laboratory services and products, announces that its laboratory operations in San Diego, California, are to be expanded to include COVID-19 qPCR testing services.
The division based in the Torrey Pines Genomics hub of the US, and home to prestigious as the Scripps Research Center, will mirror that of the Company’s set up in Nottingham, England, and is expected to be fully operational in Q2 2021.
The Group’s existing San Diego facility currently houses Stability Storage Solutions and Genomics business units and the enhanced space is planned to have the capacity to process up to circa 5,000 samples per day with opportunities for continued growth.
SourceBio already has cGMP, HPRA and FDA accredited facilitates in the UK, Ireland and United States for a global client base. The increased laboratory capacity of 1642 square feet will adhere to requirements and be fully compliant with guidelines from the FDA. The Company expects to receive the necessary accreditation to begin processing samples within the planned timeframe.
The site will also benefit from the available local labour pool which is rich in healthcare and research talent. The Company is to employ additional staff onsite who will be needed to operate a 24/7 service. The laboratory will not only serve the local community but also support SourceBio’s global partners across the United States.
Jay LeCoque, Executive Chairman, commented: “SourceBio has already processed approaching 1,000,000 COVID-19 antigen RT-PCR tests in the UK for the DHSC and the NHS, Private Hospital Groups and Commercial customers since first offering its service in May 2020.
“This further investment in our San Diego facility increases our overall capacity to increase COVID-19 qPCR testing services by up to an additional 5,000 samples per day and means we can address the clear market demand for COVID-19 testing in the US.”
Contacts:
| SourceBio International plc | ||
| Jay LeCoque, Executive Chairman |
Via Walbrook PR |
|
| Tony Ratcliffe, Chief Financial Officer | ||
|
Walbrook PR Limited |
Tel: 020 7933 8780 or sourcebio@walbrookpr.com |
|
|
Paul McManus / Sam Allen |
Mob: 07980 541 893 / 07748 651 727 |
|
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management, and care. Group revenues are derived from four core businesses areas:
- Infectious Disease Testing – a range of COVID-19 testing services for Commercial enterprises, Private Healthcare groups, NHS and the DHSC. Utilising multiple technologies (PCR, LAMPore, LAMP, Lateral Flow, Quantitative Antibody tests and Whole Genome Sequencing for positive results), SourceBio offers both screening and gold standard COVID-19 testing and operates under ISO:15189 accreditation required by the DHSC. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits (including ‘Fit to Fly’, ‘Test to Release’ and ‘2 & 8 Day International Travel’ approved tests) whilst also being the lead operator on Mobile Testing Unit services to support outbreak testing for the DHSC, event and venue testing.
- Healthcare Diagnostics – histopathology and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
- Genomics – DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
- Stability Storage – shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA; and
More details on Group operations can be found here: www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market of the London Stock Exchange.
